Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight’s lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.
Location: Israel, Center District, Hevel Modiin Regional Council
Employees: 11-50
Total raised: $78M
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Israel Bio... | ibf.fund |
| - | Arkin Hold... | arkinholdi... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.12.2020 | - | $46M | - |
| 12.03.2020 | Series C | $19M | - |
| 16.05.2016 | - | $13M | - |
Mentions in press and media 3
| Date | Title | Description |
| 02.12.2020 | Biosight Ltd. announced that it has received $46 million in funding from a group of investors | On December 2, 2020, Biosight Ltd. closed the transaction. The company has raised $46,000,000 in the transaction. The company has raised an additional $27,000,000 in the transaction. The tranche was led by returning investor Israel Biotech ... |
| 12.03.2020 | Biosight Secures $19M in Series C Funding | Biosight Ltd., a Airport City, Israel-based pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, raised $19M in Series C financing. The round was led by Israel Biotech Fund (IBF... |
| 16.05.2016 | BioSight Closes $13M in Venture Capital Funding | BioSight Ltd, a Karmiel, Israel-based pharmaceutical development company, closed $13m in funding. The round, made in two steps, the first immediate and the second expected in the upcoming year, upon completion of a milestone by the company,... |